Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: The CRYSTAL open-label randomised trial

Respiratory Research

Volumn 18, Issue 1, 2017, Pages

  Vogelmeier, Claus F ^a   Gaga, Mina ^b   Aalamian Mattheis, Maryam ^c   Greulich, Timm ^a   Marin, Jose M ^d,e   Castellani, Walter ^f   Ninane, Vincent ^g   Lane, Stephen ^h   Nunez, Xavier ⁱ   Patalano, Francesco ^c   Clemens, Andreas ^c   Kostikas, Konstantinos ^c  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b First Department of Thoracic Surgery   (Greece)

^c NOVARTIS PHARMA AG   (Switzerland)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Palagi Hospital   (Italy)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h ADELAIDE AND MEATH HOSPITAL   (Ireland)

ⁱ TFS Develop   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Direct switch; Dual bronchodilation; Indacaterol glycopyrronium; Open label

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; LONG ACTING BETA AGONIST; LONG ACTING MUSCARINIC AGONIST; MUSCARINIC AGENT; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLYCOPYRRONIUM; INDACATEROL-GLYCOPYRRONIUM COMBINATION; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; TRANSITION DYSPNEA INDEX; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFECTS; DRUG SUBSTITUTION; EUROPE; LUNG; PATHOPHYSIOLOGY; PATIENT SAFETY; QUALITY OF LIFE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG SUBSTITUTION; DYSPNEA; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HEALTH STATUS; HUMANS; INDANS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SAFETY; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLONES; RECOVERY OF FUNCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85024379997     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-017-0622-x     Document Type: Article

References (28)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from www.goldcopd.org. Accessed on 4 May 2017
2. Dransfield MT, Bailey W, Crater G, Emmett A, O'Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20:46-53.
3. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51-60.
4. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222-34.
5. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375:454-63.
6. Kruis AL, Stallberg B, Jones RC, Tsiligianni IG, Lisspers K, van der Molen T, Kocks JW, Chavannes NH. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9:e90145.
7. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from www.goldcopd.org.
8. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014;44:873-84.
9. Kon SS, Dilaver D, Mittal M, Nolan CM, Clark AL, Canavan JL, Jones SE, Polkey MI, Man WD. The clinical COPD questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. Thorax. 2014;69:793-8.
10. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest. 2007;132:1283-90.
11. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285-94.
12. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390-8.
13. Horita N, Kaneko T. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2015;10:813-22.
14. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484-94.
15. Mahler DA, Decramer M, D'Urzo A, D'Urzo A, Worth H, White T, Alagappan VK, Chen H, Gallagher N, Kulich K, Banerji D. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43:1599-609.
16. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472-86.
17. Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78.
18. Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, Caracta C, Gil EG, Leselbaum A. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
19. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Beier J, Seoane B, Segarra RM, Leselbaum A. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J 2016. 2016;48:1030-9.
20. Beeh KM, Beier J, Donohue JF. Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res. 2012;13:52.
21. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluna JJ, van der Molen T, Adamek L, Banik N. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38:29-35.
22. Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R, Leidy NK. Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest. 2012;142:134-40.
23. Beyer-Westendorf J, Buller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost. 2011;9:2153-8.
24. Beeh KM, Burgel PR, Franssen FM, Lopez-Campos JL, Loukides S, Hurst JR, Flezar M, Ulrik CS, Di Marco F, Stolz D, et al: How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2016. [Epub ahead of print].
25. Kostikas K, Saifakas NM. Does the term "deflators" reflect more accurately the beneficial effects of long-acting bronchodilators in COPD? COPD. 2016;13:537-9.
26. Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108:584-92.
27. Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015-26.
28. Patalano F, Banerji D, D'Andrea P, Fogel R, Altman P, Colthorpe P. Addressing unmet needs in the treatment of COPD. Eur Respir Rev. 2014;23:333-44.